Erlonat 150mg Tablet

Most of the side effects after taking the Erlonat 150mg tablet do not require any special medical attention and will slowly disappear with time. However, it is advised to consult your doctor if you experience these side effects persistently. Some of the side effects are discussed below:

Fever

Rash

Cough

Fatigue

Diarrhea

Hair loss Vomiting Bone pain

Constipation

Muscles pain

Appetite loss

Abdominal pain

Difficulty in breathing

Infection in the mouth and stomach

Inform your doctor immediately if you see blood in your stools after taking Erlonat 150mg Tablet.

Taking Erlonat 150mg Tablet can make your skin sensitive. So wear high SPF sunscreen while going out or exposed to direct sun rays.

​Diarrhea is the most common side effect after taking Erlonat 150mg Tablet. So, drink plenty of water and fluid to keep your body hydrated.​

Erlonat 150mg Tablet is not considered to be safe for pregnant and breastfeeding women, as it may pass through the mother and harm the baby.

It is advised to use trusted methods of birth control and contraceptive pills to delay pregnancy while under treatment with Erlonat 150mg Tablet.

Do not take antacids medicine (Medicine lowers the stomach acid) with Erlonat 150mg Tablet, as it may interact with the tablet and can affect the action.

Jiao, W., et al. (2021). Efficacy and tolerability of erlotinib 100 mg/d vs. gefitinib 250 mg/d in EGFR‑mutated advanced non‑small cell lung cancer (E100VG250): an open‑label, randomized, phase 2 study. Oncotarget, 12(10), pp.32-70.

Nishio, M., Seto, T., Reck, M., et al. (2025). Final survival outcomes with ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated EGFR‑mutated metastatic NSCLC: RELAY Japanese subset. JTO Clinical Research Reports, 6(6), 100819.

Nomura, A., et al. (2021). Efficacy of erlotinib and its effects on the quality of life of older patients with EGFR‑mutant non‑small cell lung cancer: A multicenter, dose‑modification phase II study. Geriatrics & Gerontology International, 21(3), pp. 881–886.

Smith, A., et al. (2025). Phase II trial of chemotherapy, cetuximab, and erlotinib in metastatic or recurrent head and neck squamous cell carcinoma. medRxiv. Zhao, Y., Zhang, L., Fang, W., Zhang, J., Zhang, Y., Hong, S., Ma, S., Zhou, C., Yang, J., Huang, J., Zhao, Y., & Zhang, L. (2020). Efficacy and tolerability of erlotinib 100 mg/day versus gefitinib 250 mg/day in EGFR‑mutated advanced non‑small cell lung cancer: A randomized phase II study. Journal of Thoracic Oncology.